10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 301–400 of 1,169
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Dutta, S., Shah, R. B., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M. (2023) · Drug Design, Development and Therapy · doi:10.2147/dddt.s409373 · Cited by 248
Sharma, M., Nazareth, I., & Petersen, I. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010210 · Cited by 291
“There has also been a greater awareness of the need for aggressive treatment of T2DM to reduce and delay long-term complications such as cardiovascular and renal disease.(6) Several new therapies have emerged in the past decade, such as incretin-based therapies and SGLT-2 inhibitors, making the choice of suitable anti…”
BackgroundDiabetic retinopathy: pathogenesis, clinical grading, management and future developments
Heng, L. Z., Comyn, O., Peto, T., Tadros, C., Ng, E., Sivaprasad, S., & Hykin, P. G. (2013) · Diabetic Medicine · doi:10.1111/dme.12089 · Cited by 285
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.154 · Cited by 286
Self-citationWilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., & for the Dapagliflozin 006 Study Group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12187 · Cited by 291
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62162-0 · Cited by 287
Self-citationHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 291
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
Thornberry, N. A., & Gallwitz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.004 · Cited by 268
Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes
Courcoulas, A. P., Patti, M. E., Hu, B., Arterburn, D. E., Simonson, D. C., Gourash, W. F., Jakicic, J. M., Vernon, A. H., Beck, G. J., Schauer, P. R., et al. (2024) · JAMA · doi:10.1001/jama.2024.0318 · Cited by 284
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
“Improvements in glycaemia during treatment with metformin were insufficient to explain the improved cardiovascular outcomes observed in the UKPDS [52].”
BackgroundInfluentialThe Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial
Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J. H., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebel, R. J., Yawn, B. P., Yapuncich, V., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.293 · Cited by 283
Diabetes and Cause-Specific Mortality in Mexico City
Alegre-Díaz, J., Herrington, W., López-Cervantes, M., Gnatiuc, L., Ramirez, R., Hill, M., Baigent, C., McCarthy, M. I., Lewington, S., Collins, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605368 · Cited by 283
“Renin–angiotensin system inhibitor 1,012 (16) 2,626 (6) 3,425 (27) 8,756 (10)”
Repurposing metformin: an old drug with new tricks in its binding pockets
Pryor, R., & Cabreiro, F. (2015) · Biochemical Journal · doi:10.1042/bj20150497 · Cited by 280
Histone Methyl Transferases and Demethylases; Can They Link Metabolism and Transcription?
Teperino, R., Schoonjans, K., & Auwerx, J. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.09.004 · Cited by 271
“…the sustained legacy effect of blood glucose control observed in the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study (Nathan et al., 2005; Holman et al., 2008), further mechanistic work is required to establish a role for HMTs/ HDMs in this phenomenon.”
Backgroundde Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.024 · Cited by 278
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
“The benefits of metformin in reducing microvascular disease have been supported by a 10-year follow up of the original UKPDS report (30).”
BackgroundZhou, S., Chen, H.-Z., Wan, Y.-Z., Zhang, Q.-J., Wei, Y.-S., Huang, S., Liu, J.-J., Lu, Y.-B., Zhang, Z.-Q., Yang, R.-F., et al. (2011) · Circulation Research · doi:10.1161/circresaha.111.243592 · Cited by 273
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s009 · Cited by 271
“Long-term follow-up of the UKPDS cohorts showed enduring effects of early glycemic control on most microvascular complications (42).”
BackgroundThe Role of Advanced Glycation End Products in Diabetic Vascular Complications
Rhee, S. Y., & Kim, Y. S. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.0105 · Cited by 274
Kosiborod, M., Gomes, M. B., Nicolucci, A., Pocock, S., Rathmann, W., Shestakova, M. V., Watada, H., Shimomura, I., Chen, H., Cid-Ruzafa, J., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0787-8 · Cited by 262
Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., & Ezzati, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30366-2 · Cited by 265
RetractedShurraw, S. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.537 · Cited by 269
Pharmacological treatment of hyperglycemia in type 2 diabetes
Taylor, S. I., Yazdi, Z. S., & Beitelshees, A. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142243 · Cited by 245
“(b) Intensive HbA1c-lowering early in the disease’s natural history provides long-term benefit even if ambitious HbA1c targets are not sustained permanently (5, 8).”
BackgroundInfluentialDiabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
Molitch, M. E., Adler, A. I., Flyvbjerg, A., Nelson, R. G., So, W.-Y., Wanner, C., Kasiske, B. L., Wheeler, D. C., de Zeeuw, D., & Mogensen, C. E. (2015) · Kidney International · doi:10.1038/ki.2014.128 · Cited by 268
Impact of Electronic Health Record Clinical Decision Support on Diabetes Care: A Randomized Trial
O'Connor, P. J., Sperl-Hillen, J. M., Rush, W. A., Johnson, P. E., Amundson, G. H., Asche, S. E., Ekstrom, H. L., & Gilmer, T. P. (2011) · The Annals of Family Medicine · doi:10.1370/afm.1196 · Cited by 263
Patient adherence to medication requirements for therapy of type 2 diabetes
Bailey, C. J., & Kodack, M. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02544.x · Cited by 255
Sauvé, M., Ban, K., Momen, M. A., Zhou, Y.-Q., Henkelman, R. M., Husain, M., & Drucker, D. J. (2010) · Diabetes · doi:10.2337/db09-0955 · Cited by 264
“More recently, GLP-1 (9-36), a peptide metabolite derived from native GLP-1 (7From the (1)Samuel Lunenfeld Research Institute, Mt.”
BackgroundMethodInfluentialChalmers, J., & Cooper, M. E. (2008) · New England Journal of Medicine · doi:10.1056/nejme0807625 · Cited by 263
Chaitman, B. R., Hardison, R. M., Adler, D., Gebhart, S., Grogan, M., Ocampo, S., Sopko, G., Ramires, J. A., Schneider, D., Frye, R. L., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.913111 · Cited by 263
Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment
Serhiyenko, V. A., & Serhiyenko, A. A. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i1.1 · Cited by 251
Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus
Reach, G., Pechtner, V., Gentilella, R., Corcos, A., & Ceriello, A. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.06.003 · Cited by 251
“Delays in treatment intensification can mean that patients are exposed to long-term elevations of HbA1c that can negatively impact their prognosis [6,51].”
BackgroundImpact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
“10 years to become manifest.(82,83) Therefore, prevention of CVD in T2DM patients demands a multifactorial approach to im-”
BackgroundInfluentialZoungas, S., de Galan, B. E., Ninomiya, T., Grobbee, D., Hamet, P., Heller, S., MacMahon, S., Marre, M., Neal, B., Patel, A., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0959 · Cited by 256
“Long-term follow-up of the UKPDS study (19) has also demonstrated that the cardiovascular and mortality benefits of intensive glucose control emerge over time.”
BackgroundMargolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2334 · Cited by 259
Paneni, F., Mocharla, P., Akhmedov, A., Costantino, S., Osto, E., Volpe, M., Lüscher, T. F., & Cosentino, F. (2012) · Circulation Research · doi:10.1161/circresaha.112.266593 · Cited by 256
Nathan, D. M., Buse, J. B., Kahn, S. E., Krause-Steinrauf, H., Larkin, M. E., Staten, M., Wexler, D., Lachin, J. M., & the GRADE Study Research Group (2013) · Diabetes Care · doi:10.2337/dc13-0356 · Cited by 254
“Metformin was selected as the foundation therapy according to the same rationale used in most of the recently developed consensus algorithms (15– 18), namely, its long-term clinical experience, effectiveness in lowering glycemia over a wide range of A1C levels without causing hypoglycemia, weight-neutral or weight-los…”
BackgroundMethodGillett, M., Dallosso, H. M., Dixon, S., Brennan, A., Carey, M. E., Campbell, M. J., Heller, S., Khunti, K., Skinner, T. C., & Davies, M. J. (2010) · BMJ · doi:10.1136/bmj.c4093 · Cited by 250
“assessed patients with established type 2 diabetes. However, economic evaluations of these studies have not been undertaken. The need to offer optimal intervention from diagnosis in patients with diabetes is supported by the legacy effect observed from the long term follow-up data of the UKPDS.”
BackgroundKhunti, K., Nikolajsen, A., Thorsted, B. L., Andersen, M., Davies, M. J., & Paul, S. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12626 · Cited by 256
“The duration of the present study was not sufficient to assess whether failure to intensify treatment leads to poorer clinical outcomes; however, the findings of the UKPDS suggest that, particularly in younger patients, this is likely to be the case [6].”
BackgroundResultInfluentialSelf-citationEvaluating the Role of Epigenetic Histone Modifications in the Metabolic Memory of Type 1 Diabetes
Miao, F., Chen, Z., Genuth, S., Paterson, A., Zhang, L., Wu, X., Li, S. M., Cleary, P., Riggs, A., Harlan, D. M., et al. (2014) · Diabetes · doi:10.2337/db13-1251 · Cited by 253
“Similar “legacy effects” of prior strict glycemic control were also observed in the UK Prospective Diabetes Study (15,16).”
BackgroundShigiyama, F., Kumashiro, N., Miyagi, M., Ikehara, K., Kanda, E., Uchino, H., & Hirose, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0564-0 · Cited by 249
Thompson, A., Fleischmann, K. E., Smilowitz, N. R., de las Fuentes, L., Mukherjee, D., Aggarwal, N. R., Ahmad, F. S., Allen, R. B., Altin, S. E., Auerbach, A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.013 · Cited by 209
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
“These effects were significantly blocked by the GLP-1 antagonist, exendin (9-39)(120).”
BackgroundInfluentialThe Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
Caussy, C., Aubin, A., & Loomba, R. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01383-7 · Cited by 230
Simmons, R. K., Echouffo-Tcheugui, J. B., Sharp, S. J., Sargeant, L. A., Williams, K. M., Prevost, A. T., Kinmonth, A. L., Wareham, N. J., & Griffin, S. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61422-6 · Cited by 252
Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges
Sneddon, J. B., Tang, Q., Stock, P., Bluestone, J. A., Roy, S., Desai, T., & Hebrok, M. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.016 · Cited by 250
Pratley, R., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Garber, A., Thomsen, A. B., Hartvig, H., Davies, M., et al. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02656.x · Cited by 253
Zambrowicz, B., Freiman, J., Brown, P. M., Frazier, K. S., Turnage, A., Bronner, J., Ruff, D., Shadoan, M., Banks, P., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 243
Storgaard, H., Gluud, L. L., Bennett, C., Grøndahl, M. F., Christensen, M. B., Knop, F. K., & Vilsbøll, T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166125 · Cited by 237
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Best, J. H., Hoogwerf, B. J., Herman, W. H., Pelletier, E. M., Smith, D. B., Wenten, M., & Hussein, M. A. (2011) · Diabetes Care · doi:10.2337/dc10-1393 · Cited by 251
“The UK Prospective Diabetes Study (UKPDS) reported a significant reduction in MI in the small cohort treated with metformin (6), but effects with sulfonylureas and insulin did not achieve statistical significance until the 10-year follow-up study (7,8).”
BackgroundPreservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Halperin, F., Ding, S.-A., Simonson, D. C., Panosian, J., Goebel-Fabbri, A., Wewalka, M., Hamdy, O., Abrahamson, M., Clancy, K., Foster, K., et al. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2014.514 · Cited by 245
“(%) Male 6 (32) 9 (47) Female 13 (68) 10 (53) Race/ethnicity, No.”
The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease
Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., & Iskandrian, A. E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.047 · Cited by 247
Protective Factors and the Pathogenesis of Complications in Diabetes
Yu, M. G., Gordin, D., Fu, J., Park, K., Li, Q., & King, G. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad030 · Cited by 228
Impact of Diabetes Mellitus on Bone Health
Murray, C. E., & Coleman, C. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194873 · Cited by 228
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.094 · Cited by 223
“International Reports (2022) 7, 1463–1476 apparent shortly after drug initiation suggesting mechanisms independent of glycemic control.(6) On the basis of emerging evidence, SGLT2 inhibitors are now transforming the management of heart failure and CKD in patients with and without T2DM.”
Background10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Ovalle, F. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79372-2 · Cited by 236
Zhao, Z., Li, X., Jian, D., Hao, P., Rao, L., & Li, M. (2017) · Acta Diabetologica · doi:10.1007/s00592-016-0943-0 · Cited by 244
“Multiple largescale investigations have revealed that intensive glucoselowing therapy in the early phases of T2DM can benefit patients substantially, reducing the incidences of macrovascular and microvascular complications [26, 27].”
BackgroundPsychological family intervention for poorly controlled type 2 diabetes.
Keogh, K. M., Smith, S. M., White, P., McGilloway, S., Kelly, A., Gibney, J., & O’Dowd, T. (2011) · PubMed · Cited by 282
Metformin: An Old Drug with New Applications
Zhou, J., Massey, S., Story, D., & Li, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102863 · Cited by 233
Microneedles for Transdermal Biosensing: Current Picture and Future Direction
Ventrelli, L., Marsilio Strambini, L., & Barillaro, G. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500450 · Cited by 235
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237
“E arly intervention to improve glycemic control reduces microvascular complications in type 2 diabetes (1–4) and may provide long-term macrovascular benefits (5).”
BackgroundHuo, X., Gao, L., Guo, L., Xu, W., Wang, W., Zhi, X., Li, L., Ren, Y., Qi, X., Sun, Z., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00508-2 · Cited by 236
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.012 · Cited by 237
Caprio, F. Z., & Sorond, F. A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.001 · Cited by 219
Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON
Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2322 · Cited by 240
“Post-trial follow-up of the UK Prospective Diabetes Study (UKPDS) cohort of newly diagnosed patients with type 2 diabetes (7) and the Diabetes Control and Complications Trial (DCCT) cohort of young patients with type 1 diabetes (8) showed a sustained benefit for microvascular complications, beyond the period of intens…”
BackgroundSelf-citationGlycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
Cryer, P. E. (2014) · Diabetes · doi:10.2337/db14-0059 · Cited by 236
“In the UKPDS follow-up, former intensive glycemic therapy was associated with reduced myocardial infarction and all-cause mortality in type 2 diabetes (16).”
BackgroundInfluentialEpigenetic phenomena linked to diabetic complications
Pirola, L., Balcerczyk, A., Okabe, J., & El-Osta, A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.188 · Cited by 239
“These improved outcomes in this follow-up, secondary analysis occurred despite disappearance of the difference in HbA 1c levels between the standard-treatment and intensive-treatment groups”
BackgroundTesta, R., Bonfigli, A. R., Prattichizzo, F., La Sala, L., De Nigris, V., & Ceriello, A. (2017) · Nutrients · doi:10.3390/nu9050437 · Cited by 225
“In this trial, people who underwent intensive treatment had fewer vascular complications and fewer adverse clinical outcomes over time as compared to people who underwent standard treatment, despite showing similar HbA1c value in the long-term follow-up that ensued [3,9].”
BackgroundKotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., Reiner, Ž., Keil, U., & EUROASPIRE Study Group (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283383f30 · Cited by 238
Identification of barriers to insulin therapy and approaches to overcoming them
Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238
“associated with significantly decreased risks of myocardial infarction, death from any cause and microvascular disease.(3) In addition, a retro-”
BackgroundThe Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
Clinical inertia to insulin initiation and intensification in the UK: A focused literature review
Khunti, K., & Millar-Jones, D. (2017) · Primary Care Diabetes · doi:10.1016/j.pcd.2016.09.003 · Cited by 235
Validation of the IMS CORE Diabetes Model
McEwan, P., Foos, V., Palmer, J. L., Lamotte, M., Lloyd, A., & Grant, D. (2014) · Value in Health · doi:10.1016/j.jval.2014.07.007 · Cited by 235
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236
“As a result of loss of body salt, the extracellular fluid volume contracts (3) and leads to a decrease of atrial natriuretic peptides, which may result in vasoconstriction of the afferent arterioles.”
BackgroundRomagnani, P., Agarwal, R., Chan, J. C. N., Levin, A., Kalyesubula, R., Karam, S., Nangaku, M., Rodríguez-Iturbe, B., & Anders, H.-J. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00589-9 · Cited by 184
“In T2DM, the long-term effects of early and intensive blood glucose control led to reduced incidence of all adverse events, including death decades later 191,192 .”
Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60746-5 · Cited by 235
Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications
Kalil, G. Z., & Haynes, W. G. (2012) · Hypertension Research · doi:10.1038/hr.2011.173 · Cited by 221
Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M. (2015) · Diabetes · doi:10.2337/db14-0694 · Cited by 226
“In the extended follow-up of the UKPDS subjects, the initial intensive therapy for 10 years had a legacy effect in maintaining lower rates of myocardial infarction and all-cause mortality (Table 1) (47).”
BackgroundMetformin attenuates cardiac fibrosis by inhibiting the TGFβ1–Smad3 signalling pathway
Xiao, H., Ma, X., Feng, W., Fu, Y., Lu, Z., Xu, M., Shen, Q., Zhu, Y., & Zhang, Y. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq066 · Cited by 231
“The United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that metformin had cardiovascular protective actions beyond its antihyperglycaemic properties.(1,2) The possible mechanisms include reducing insulin resistance, improving lipid metabolism, and decreasing hypercoagulation, as well as favourable actions…”
Background2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Lincoff, A. M., Tardif, J.-C., Schwartz, G. G., Nicholls, S. J., Rydén, L., Neal, B., Malmberg, K., Wedel, H., Buse, J. B., Henry, R. R., et al. (2014) · JAMA · doi:10.1001/jama.2014.3321 · Cited by 231
Chronic Hyperglycemia and Glucose Toxicity: Pathology and Clinical Sequelae
Campos, C. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2615 · Cited by 219
“A 10-year follow-up to the UKPDS reported similar findings.(34) Despite the difference in HbA 1c”
BackgroundResultDiabetic kidney diseases revisited: A new perspective for a new era
Fu, H., Liu, S., Bastacky, S. I., Wang, X., Tian, X.-J., & Zhou, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.005 · Cited by 226
“com 10-year follow-up study in T2DM patients found continued benefits of intensive glycemic control on micro- and macrovascular risks and death [95,96].”
BackgroundCardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K. E., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 212
7. Approaches to Glycemic Treatment
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 225
Intensive glucose control in patients with type 2 diabetes - 15-year follow-up.
Reaven, P. D., Emanuele, N. V., Wiitala, W. L., Bahn, G. D., Reda, D. J., McCarren, M., Duckworth, W. C., & Hayward, R. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806802 · Cited by 228
Zhang, Y., Hu, G., Yuan, Z., & Chen, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042551 · Cited by 226
“However, these studies were constrained by inherent limitations of the clinical trials, which might have been underpowered to show clinical benefits - especially if event rates were lower than expected or the studies had a high lost follow-up rate [14].”
BackgroundCardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60794-7 · Cited by 227
Self-citationForbes, A., Murrells, T., Mulnier, H., & Sinclair, A. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30048-2 · Cited by 223
Maggard-Gibbons, M., Maglione, M., Livhits, M., Ewing, B., Maher, A. R., Hu, J., Li, Z., & Shekelle, P. G. (2013) · JAMA · doi:10.1001/jama.2013.4851 · Cited by 223
Effect of diet on type 2 diabetes mellitus: A review.
(2017) · Europe PMC (PubMed Central) · Cited by 226
Vinagre, I., Mata-Cases, M., Hermosilla, E., Morros, R., Fina, F., Rosell, M., Castell, C., Franch-Nadal, J., Bolíbar, B., & Mauricio, D. (2012) · Diabetes Care · doi:10.2337/dc11-1679 · Cited by 217
Wysham, C., Bhargava, A., Chaykin, L., de la Rosa, R., Handelsman, Y., Troelsen, L. N., Kvist, K., & Norwood, P. (2017) · JAMA · doi:10.1001/jama.2017.7117 · Cited by 221
“73 m2); (3) hypoglycemic symptom unawareness; (4) exposure to insulin for longer than 5 years; or (5) an episode of hypoglycemia (symptoms and/or blood glucose level ≤70 mg/dL [to convert to millimoles per liter, multiply by 0.”
BackgroundBirkeland, K. I., Bodegard, J., Eriksson, J. W., Norhammar, A., Haller, H., Linssen, G. C. M., Banerjee, A., Thuresson, M., Okami, S., Garal‐Pantaler, E., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14074 · Cited by 223
Cardoso, C. R. L., Leite, N. C., Moram, C. B. M., & Salles, G. F. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0677-0 · Cited by 222
Kashtoh, H., & Baek, K.-H. (2023) · Plants · doi:10.3390/plants12162944 · Cited by 188
“These chronic metabolic disorders may result in neuropathy, retinopathy, angiopathy, and nephropathy [11].”
BackgroundPirola, L., Balcerczyk, A., Tothill, R. W., Haviv, I., Kaspi, A., Lunke, S., Ziemann, M., Karagiannis, T., Tonna, S., Kowalczyk, A., et al. (2011) · Genome Research · doi:10.1101/gr.116095.110 · Cited by 223
“abetes Control and Complications Trial 2002) and follow-up studies (Holman et al. 2008; Nathan et al. 2009) indicate that the establishment of tight glycemic control is critical for long-term control of diabetes.”
BackgroundEkström, N., Schiöler, L., Svensson, A.-M., Eeg-Olofsson, K., Miao Jonasson, J., Zethelius, B., Cederholm, J., Eliasson, B., & Gudbjörnsdottir, S. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001076 · Cited by 221
“The UKPDS demonstrated a reduction in all-cause mortality in the subgroup of obese DM2 patients treated with metformin compared with diet, SU or insulin,(2) also confirmed in a 10-year post-interventional follow-up.(3) Furthermore, several recent observational studies have reported reduced risk with metformin compared…”
Result
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.